POS0370 2023 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF FATIGUE IN PEOPLE WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES
Authors: E. Dures, B. Farisogullari, E. Santos, A. Moltó, C. Feldthusen, C. Harris, C. Elling-Audersch, D. Connolly, E. Elefante, F. Estevez-Lopez, I. Bini, J. Primdahl, K. Hoeper, M. Urban, M. V. D. Laar, M. Redondo, P. Böhm, R. Amarnani, R. Hayward, R. Geenen, S. Rednic, S. Pettersson, T. Thomsen, T. Uhlig, V. Ritschl, P. Machado
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognised as one of the most challenging symptoms to manage [1]. The existence of multiple factors associated with fatigue, the lack of clarity around underlying pathophysiological mechanisms and the limited evidence about what helps have led to a multifaceted and often fragmented approach to symptom management. However, there are no recommendations for fatigue management in people with I-RMDs, and this lack of guidance has been challenging for those living with fatigue as well as for healthcare professionals delivering clinical care. <h3>Objectives</h3> To develop EULAR recommendations for the management of fatigue in people with I-RMDs. <h3>Methods</h3> A multi-disciplinary taskforce comprising 26 members from 14 European countries was convened and two systematic reviews were conducted. The taskforce developed recommendations based on evidence from the systematic reviews and taskforce members' personal and professional experience of fatigue in I-RMDs. <h3>Results</h3> Four overarching principles and four recommendations were developed (Table 1), including health professionals' awareness that fatigue should be monitored and assessed and that people with I-RMDs should be offered management options. Shared decisions about fatigue management should consider the needs and preferences of individuals, their clinical disease activity, comorbidities and other psychosocial and contextual factors (<b>Table 1</b>). <h3>Conclusion</h3> These 2023 EULAR recommendations provide consensus and up-to-date guidance on the management of fatigue in people with I-RMDs. <h3>Reference</h3> [1]Dures E, et al. Fatigue in inflammatory arthritis. Best Pract Res Clin Rheumatol 2020;34. <h3>Acknowledgements</h3> B Farisogullari and E Santos contributed equally to the manuscript. <h3>Disclosure of Interests</h3> Emma Dures: None declared, Bayram Farisogullari: None declared, Eduardo Santos: None declared, Anna Moltó: None declared, Caroline Feldthusen: None declared, Claire Harris: None declared, Corinna Elling-Audersch: None declared, Deirdre Connolly: None declared, Elena Elefante: None declared, Fernando Estevez-Lopez: None declared, Ilaria Bini: None declared, Jette Primdahl: None declared, Kirsten Hoeper Speakers bureau: AbbVie, Novartis, Galapagos, Consultant of: AbbVie, Novartis, Galapagos, Marie Urban: None declared, Mart van de Laar: None declared, Marta Redondo: None declared, Peter Böhm: None declared, Raj Amarnani: None declared, Rhys Hayward Speakers bureau: Abbvie, Rinie Geenen: None declared, Simona Rednic: None declared, Susanne Pettersson: None declared, Tanja Thomsen: None declared, Till Uhlig: None declared, Valentin Ritschl: None declared, Pedro Machado Speakers bureau: Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, Consultant of: Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB.